BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LY03020 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LY03020\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07396870-710@assetmemo.bio
DTSTAMP:20261121T004544Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:LY03020: Phase 2 readout est. (NCT07396870)
DESCRIPTION:LY03020\, phase 2\, Schizophrenia.\nStudy: A Phase 2 Study to E
 valuate the Efficacy and Safety of LY03020 in Acutely Psychotic Participan
 ts With Schizophrenia\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ly03020#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07396870
URL:https://assetmemo.bio/drug/ly03020#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
